Davis's Drug Guide
lamivudine/raltegravir
General
**Off Market Drug**
This medication is no longer available in the United States. Information provided here is for reference purposes only.
Pronunciation:
la-mi-vyoo-deen/ral-teg-ra-veer
To hear audio pronunciation of this topic, purchase a subscription or log in.Trade Name(s)
- Dutrebis
Ther. Class.
none assigned
Pharm. Class.
nucleoside reverse transcriptase inhibitors
integrase strand transfer inhibitors instis
There's more to see -- the rest of this topic is available only to subscribers.
Citation
Vallerand, April Hazard., et al. "Lamivudine/raltegravir." Davis's Drug Guide, 18th ed., F.A. Davis Company, 2023. Pediatrics Central, peds.unboundmedicine.com/pedscentral/view/Davis-Drug-Guide/110367/all/lamivudine_raltegravir.
Vallerand AHA, Sanoski CAC, Quiring CC. Lamivudine/raltegravir. Davis's Drug Guide. F.A. Davis Company; 2023. https://peds.unboundmedicine.com/pedscentral/view/Davis-Drug-Guide/110367/all/lamivudine_raltegravir. Accessed November 30, 2023.
Vallerand, A. H., Sanoski, C. A., & Quiring, C. (2023). Lamivudine/raltegravir. In Davis's Drug Guide (18th ed.). F.A. Davis Company. https://peds.unboundmedicine.com/pedscentral/view/Davis-Drug-Guide/110367/all/lamivudine_raltegravir
Vallerand AHA, Sanoski CAC, Quiring CC. Lamivudine/raltegravir [Internet]. In: Davis's Drug Guide. F.A. Davis Company; 2023. [cited 2023 November 30]. Available from: https://peds.unboundmedicine.com/pedscentral/view/Davis-Drug-Guide/110367/all/lamivudine_raltegravir.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - lamivudine/raltegravir
ID - 110367
A1 - Sanoski,Cynthia A,
AU - Vallerand,April Hazard,
AU - Quiring,Courtney,
BT - Davis's Drug Guide
UR - https://peds.unboundmedicine.com/pedscentral/view/Davis-Drug-Guide/110367/all/lamivudine_raltegravir
PB - F.A. Davis Company
ET - 18
DB - Pediatrics Central
DP - Unbound Medicine
ER -
